Roche will be collaborating with BioNTech to develop personalized vaccines based on BioNTech’s mRNA products combined with Roche’s PD-L1 checkpoint inhibitor, Tecentriq (atezolizumab), which was approved for bladder cancer in May 2016. Continue reading
Tag Archives: dendritic cells
Cell-based Immunotherapies in the News
Baxalta, the biopharmaceutical spinoff of Baxter, entered into a $1.7 B deal with Precision BioSceinces for 6 CAR-T (Chimeric Antigen Receptor T-cell) projects, and Saronic Biotechnology announced positive data in preclinical studies of its autologous dendritic cell vaccine for hepatocellular carcinoma. Continue reading
Argos’ Metastatic Renal Cell Carcinoma Study Passes Independent Data Safety Monitoring Committee Second Interim Analysis
An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading
CD40 Antibody for Immunotherapy of Cancer Licensed by Janssen from Alligator
Janssen Biotech acquired a worldwide license to Alligator Bioscience’s Phase I immunotherapy ADC-1013, an agonistic monoclonal antibody that targets CD40, an immuno-stimulatory receptor found on antigen-presenting cells, which can spur an increase in T cells attacking a tumor. Continue reading
Stealth Nanoparticles To Reach Macrophages in Lymph Nodes
Antigen Presenting Cells (APc’s – dendritic cells, monocytes, and macrophages) are the key to provoking a robust adaptive immune response. But are all APC’s created equally in this regard? Not exactly. Continue reading
The Texas 2 Step Approach to Cancer Cyberwarfare via Exosomes
Multi-modality (surgery, chemo, radiation) therapy and combination chemotherapy (e.g, CHOP and ABVD) have long been the mainstays of treating cancer. So, we should not be surprised to read about the discovery made by scientists at Rice University and MD Anderson regarding a two-step approach involving radiation and immunotherapy. Continue reading